In 2006, three NIH pharmacologists published a 74-page review in Pharmacological Reviews that became the field's reference bible — cataloging how the endocannabinoid system could be targeted for obesity, pain, cardiovascular disease, neurodegeneration, cancer, and a dozen other conditions.
Researchers, clinicians, or advanced readers wanting a comprehensive overview of the endocannabinoid system's role across medicine — from obesity to osteoporosis, pain to Parkinson's.
74 pagescovering 15+ disease categories in a single journal article — the most comprehensive review of endocannabinoid pharmacotherapy ever published, cited nearly 3,000 times
The Backstory
By 2006, the endocannabinoid system had been studied in thousands of papers across dozens of medical fields. THC had been characterized. CB1 and CB2 had been cloned. Anandamide and 2-AG had been discovered. The enzymes that make and break them had been mapped. Individual labs were publishing individual findings in individual disease areas — pain here, obesity there, neurodegeneration somewhere else.
But nobody had connected it all. No single document existed that said: here is everything the endocannabinoid system does, everywhere it does it, and how we might target it therapeutically.
At the National Institute on Alcohol Abuse and Alcoholism in Bethesda, Maryland — an alcohol research institute, not a cannabis lab — three pharmacologists decided to write that document.
It took 74 pages.
74 Pages, 15 Diseases, One System
74
pages in a single journal article — covering over 15 disease categories from obesity to osteoporosis. Published in Pharmacological Reviews, the field's most prestigious review journal, it became the #5 most-cited paper in all of pharmacology for 2006-2009, accumulating nearly 3,000 citations.
Most review articles are 10-20 pages. At 74 pages, this wasn't a review. It was an encyclopedia.
Pacher et al. (2006), Pharmacol Rev 58:389-462; Scopus citation metrics
Pál Pacher, Sándor Bátkai, and George Kunos were Hungarian-born pharmacologists working at the NIH. Pacher — who would go on to become one of the most highly cited researchers in the world (h-index 137, over 68,000 citations) — had trained in cardiovascular physiology. Kunos, the lab chief, was NIAAA's Scientific Director. Their primary expertise wasn't cannabis. It was how lipid signaling systems affect the heart, the liver, and metabolism.
That perspective is what made the review different. They didn't approach the endocannabinoid system as a cannabis-research team studying drug effects. They approached it as pharmacologists asking: where in the body does this system matter, and how can we make drugs that target it?
The answer was: everywhere.
Not About Cannabis
Myth vs. Reality
The endocannabinoid system is the body's response to cannabis — it matters mostly for understanding how marijuana works.
The ECS is a fundamental regulatory system involved in obesity, cardiovascular disease, liver fibrosis, bone metabolism, cancer, immune disorders, neurodegeneration, and more. Cannabis research led to its discovery, but the system's importance extends far beyond any recreational or medicinal use of the plant.
The Evidence
The Pacher 2006 review documents endocannabinoid system involvement in at least 15 disease categories. Most of the therapeutic targets it identifies — obesity, atherosclerosis, osteoporosis, hepatic fibrosis — have nothing to do with cannabis use. The ECS regulates energy balance, inflammation, cell death, and tissue remodeling throughout the body.
Pacher et al. (2006), Pharmacol Rev 58:389-462
This distinction matters. When people hear "endocannabinoid system," they think "the thing cannabis activates." But the ECS existed for hundreds of millions of years before cannabis plants evolved. It regulates energy balance in every cell. It modulates immune responses in every tissue. It fine-tunes synaptic transmission in every brain circuit. Cannabis happens to contain molecules that interact with it — but the system wasn't built for cannabis any more than opioid receptors were built for poppy plants.
The Pacher review was the first document to comprehensively demonstrate the scope of that distinction.
The Map of Everything the ECS Touches
Results
Disease Areas Covered in the Review
Pacher et al. (2006), Pharmacol Rev 58:389-462
The scope is staggering. The review wasn't an overview of "what cannabis does" — it was a systematic accounting of every tissue in the body where endocannabinoid signaling had been shown to play a physiological or pathological role. The endocannabinoid system isn't a brain system that happens to exist elsewhere. It's a body-wide regulatory network that happens to be densest in the brain.
For readers coming from the cannabis side, this reframing is essential. When you use cannabis, you're not activating a niche pathway. You're flooding one of the most widespread signaling systems in human biology — which is why the effects touch everything from appetite to heart rate to mood to memory to pain perception simultaneously.
Three Roads to Medicines
The review's lasting contribution wasn't just the disease map. It was a pharmacological framework — three strategies for making drugs that target the endocannabinoid system, each designed to avoid the problems of simply giving people THC.
Process
Three Strategies for Endocannabinoid Pharmacotherapy
Strategy 1: Block CB1
Blocking the CB1 receptor suppresses appetite, reduces body weight, and improves metabolic markers. The drug rimonabant was developed for obesity using this approach. It was approved in Europe in 2006 — the same year this review was published.
Strategy 2: Boost Endocannabinoids
Instead of directly activating receptors, inhibit the enzymes that break down anandamide (FAAH) or 2-AG (MAGL). This raises endocannabinoid levels indirectly — amplifying the body's own signals rather than flooding the system with an external agonist. Theoretically more precise, fewer side effects.
Strategy 3: Activate CB2 Selectively
CB2 receptor activation reduces inflammation and provides pain relief without psychoactive effects (since CB2 is primarily on immune cells, not brain neurons). CB2-selective agonists could treat inflammatory pain, autoimmune conditions, and neuroinflammation without producing a high.
Pacher et al. (2006), Pharmacol Rev 58:389-462
The logic of each strategy was sound. The preclinical evidence supporting each was extensive. In 2006, the field was more optimistic about endocannabinoid drug development than it had ever been — or would be again.
What Actually Happened
The decade after this review was published tested every one of those strategies. The results were humbling.
Research Timeline
From Peak Optimism to Complicated Reality
This review published — the field's reference bible
74 pages mapping the therapeutic landscape at the moment of maximum optimism
Rimonabant (CB1 antagonist) approved in Europe for obesity
Strategy 1 reaches the market — weight loss works, metabolic markers improve
FDA declines to approve rimonabant for the US market
Concerns about psychiatric adverse events — depression, anxiety, suicidality
Rimonabant withdrawn from European market
Post-marketing psychiatric adverse events confirm the FDA's concerns. Strategy 1 collapses.
BIA 10-2474 (FAAH inhibitor) trial disaster in France
One volunteer dies, five hospitalized with brain hemorrhage. Strategy 2 takes a devastating hit.
LY2828360 (CB2 agonist) fails Phase 2 for osteoarthritis pain
Strategy 3 doesn't translate from animals to humans
FDA approves Epidiolex (CBD) for epilepsy
The first cannabis-derived drug approval — not from any of the three strategies, but from a different path entirely
Next-generation approaches: peripherally-restricted CB1 antagonists, allosteric modulators, MAGL inhibitors
The field isn't dead — it's learning from failure and developing more precise tools
EMA/FDA records; Pacher & Kunos (2013), FEBS J; clinical trial databases
Strategy 1 (Block CB1) produced rimonabant — a drug that worked beautifully for weight loss but caused depression and suicidal ideation because CB1 receptors are woven into the brain's mood and reward circuitry. You can't block the most abundant receptor in the brain without psychiatric consequences. Approved in Europe in 2006, withdrawn by 2008. The FDA never approved it.
Strategy 2 (Boost endocannabinoids) seemed safer — you're amplifying the body's own signals rather than introducing a foreign molecule. But in January 2016, a Phase 1 trial of BIA 10-2474 (a FAAH inhibitor) at a contract research organization in Rennes, France, resulted in the death of one healthy volunteer and hospitalization of five others with brain hemorrhages. The compound turned out to have off-target effects unrelated to FAAH. It was the worst clinical trial disaster in France in decades.
Strategy 3 (Activate CB2) was supposed to be the safest — non-psychoactive, anti-inflammatory, pain-relieving. Preclinical data in animals was consistently impressive. But when CB2 agonists reached human trials, they failed. LY2828360 showed no significant pain reduction in osteoarthritis. Species differences in CB2 expression patterns — the receptor is distributed differently in humans than in rodents — likely explain the translation failure.
Why This Paper Still Matters
The three strategies didn't fail because the review was wrong. They failed because the endocannabinoid system is more nuanced than first-generation drugs could handle. Blocking CB1 everywhere in the brain is too crude. Globally inhibiting FAAH needs exquisite selectivity. CB2 biology differs between species in ways nobody anticipated in 2006.
But the framework holds. Current drug development still follows the review's logic — just with more precision:
- Peripherally-restricted CB1 antagonists that stay out of the brain, targeting metabolic disease without psychiatric risk
- MAGL inhibitors that boost 2-AG rather than anandamide, with fewer off-target concerns than FAAH inhibitors
- Allosteric modulators that fine-tune CB1 signaling rather than blocking it completely
- Combination approaches using low-dose cannabinoids with other therapeutic agents
And then there was Epidiolex — CBD approved for epilepsy in 2018 — which came from a different direction entirely. Not a synthetic molecule targeting a specific ECS component, but a plant-derived compound with complex, multi-target pharmacology. Sometimes the plant knows something the drug designers haven't figured out yet.
“Modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions.”
— Pál Pacher, Sándor Bátkai, George Kunos, 2006
NIAAA/NIH, Bethesda, Maryland
The opening premise of the review — validated by subsequent research, complicated by clinical reality
Related Research
The System This Review Mapped
The Pacher 2006 review synthesized everything known about the endocannabinoid system's therapeutic potential. These are the discovery papers that built the system it describes.
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda et al. (1990)
CB1 — the receptor most of the review revolves around, and the target of rimonabant
Molecular characterization of a peripheral receptor for cannabinoids
Munro et al. (1993)
CB2 — the 'non-psychoactive' receptor the review identifies as the most promising drug target
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
Devane, Hanuš, Mechoulam et al. (1992)
Anandamide — the endocannabinoid the review proposes boosting by inhibiting FAAH
A second endogenous cannabinoid that modulates long-term potentiation
Stella et al. (1997)
2-AG — the dominant endocannabinoid whose degradation enzyme (MAGL) is now a leading drug target
Why is a review paper ranked among the most important studies in cannabis science?
Because it was the first document to comprehensively demonstrate that the endocannabinoid system isn't just about cannabis — it's involved in obesity, cardiovascular disease, neurodegeneration, cancer, bone metabolism, immune disorders, and more. At 74 pages covering 15+ disease categories with nearly 3,000 citations, it became the reference that organized the entire field. Individual discovery papers found pieces; this review assembled the map.
Did the drug strategies proposed in this review actually work?
Each strategy produced valuable knowledge but also significant setbacks. CB1 antagonism (rimonabant) worked for weight loss but caused psychiatric side effects and was withdrawn. FAAH inhibition was promising until a disastrous clinical trial in 2016 killed one volunteer. CB2 agonism worked in animals but has failed in human trials. However, the framework isn't wrong — current drug development uses more precise versions of the same strategies: peripherally-restricted compounds, allosteric modulators, and combination approaches. And CBD's approval for epilepsy in 2018 showed that cannabinoid-based medicines can reach patients through unexpected paths.
What the researchers found
The review comprehensively documented that the endocannabinoid system regulates pathophysiology across at least 15 disease categories: obesity and metabolic syndrome, neuropathic and cancer pain, multiple sclerosis and spasticity, movement disorders (Parkinson's, Huntington's, Tourette's), mood and anxiety disorders, schizophrenia, glaucoma, cardiovascular disease (hypertension, myocardial infarction, atherosclerosis, stroke), cancer, osteoporosis, liver disease, gastrointestinal disorders, reproductive disorders, and immune/inflammatory conditions. Three pharmacological strategies were identified: CB1 receptor antagonism (e.g., rimonabant for obesity), inhibition of endocannabinoid-degrading enzymes (FAAH, MAGL) to enhance endocannabinoid tone indirectly, and selective CB2 receptor agonism for anti-inflammatory effects without psychoactivity.
Why it matters
This review established the endocannabinoid system as far more than a cannabis-response pathway — it's a fundamental regulatory system involved in virtually every major disease category. By organizing thousands of scattered findings into a single 74-page framework, it became the roadmap for a generation of drug development. The three therapeutic strategies it articulated — CB1 antagonism, enzyme inhibition, CB2 agonism — still organize the field today, even though the first drugs based on each strategy largely failed. The review's citation impact (#5 in all of pharmacology) reflects its role as the field's central reference.
How the study worked
This is a comprehensive narrative review synthesizing published preclinical and clinical evidence across all known therapeutic applications of the endocannabinoid system as of 2006. The authors systematically organized findings by disease category, evaluating evidence quality from in vitro studies through animal models to human clinical trials. Key clinical data on rimonabant trials (1,507-3,045 patients) and cannabinoid pain studies were tabulated.
What this study cannot tell us
As a narrative review, this paper synthesizes and interprets existing evidence rather than generating new data. The disease-by-disease organization may overstate the readiness of certain therapeutic areas where evidence was primarily preclinical (animal models). The review was published at a moment of high optimism (rimonabant had just been approved) and may underweight risks that became apparent later. Some therapeutic strategies described (CB1 antagonism for obesity) subsequently failed in ways the review did not predict.
How to read the evidence
Rated strong because this is the most comprehensive and most-cited review in endocannabinoid pharmacology. Published in Pharmacological Reviews (the field's top review journal), it synthesizes evidence across all major therapeutic areas and its framework has organized the field for nearly two decades.
When this study was published
Published in 2006, this 20-year-old review captures the field at a pivotal moment — after the core discoveries but before the clinical disappointments. Its disease-area mapping and therapeutic strategy framework remain current. An updated companion paper by the same authors was published in 2013 (FEBS Journal) incorporating the lessons of rimonabant's failure.
The bigger picture
The review captured the endocannabinoid field at its moment of maximum optimism — rimonabant was being approved in Europe, FAAH inhibitors were entering development, CB2 agonists showed preclinical promise. What followed was more complicated: rimonabant was withdrawn due to psychiatric side effects (2008), a FAAH inhibitor killed a volunteer in a French trial (BIA 10-2474, 2016), and CB2 agonists failed Phase 2 trials. But the field didn't die. Epidiolex (CBD) was approved in 2018, peripherally-restricted CB1 antagonists and allosteric modulators are in development, and MAGL inhibitors show promise for neuroinflammation. The review's framework remains correct — the execution is just harder than expected.
Questions still open
- Can the endocannabinoid system be therapeutically targeted without the side effects that derailed rimonabant and BIA 10-2474?
- Which of the 15+ disease areas identified will be the first to yield an approved endocannabinoid-based drug beyond Epidiolex?
- Are peripherally-restricted compounds or allosteric modulators the path forward?
Common questions
Why is a review paper ranked as one of the most important studies in cannabis science?
Did the therapeutic strategies proposed in this review actually lead to drugs?
Read the original research
The endocannabinoid system as an emerging target of pharmacotherapy
Pharmacological Reviews, 58(3), 389-462
Citation
Pacher, P; Bátkai, S; Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462. https://doi.org/10.1124/pr.58.3.2